Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Breakthrough T1D Canada is pleased to support 3 new trainees in partnership with the Canadian Islet Research and Training Network

Breakthrough T1D Canada is thrilled to continue a successful partnership with the Canadian Islet Research and Training Network (CIRTN) and announce a third cohort of co-funded trainees beginning in 2025.

CIRTN was established in 2020 as a world-class training and research network with joint contributions from the University of Alberta, University of British Columbia, University of Manitoba, Université de Montréal, Institut de Recherches Cliniques de Montréal, and the University of Toronto and now includes 12 institutions from across Canada.  Breakthrough T1D Canada has partnered with CIRTN to leverage funding to this network from the National Science and Engineering Research Council – Collaborative Research and Training Experience (NSERC-CREATE) program. 

See 2023 cohort trainees here. See 2024 cohort trainees here. 

Dr. Summer Helmi

Postdoctoral Fellow

Supervisor: Dr. Andrew Pepper, University of Alberta

Optimizing Neonatal Porcine Islet Differentiation Using the PBS Mini Vertical-Wheel ® Bioreactor: Advancing Xenotransplantation for Type 1 Diabetes

This innovative project explores a promising approach to treating type 1 diabetes using neonatal porcine islets (NPIs) as a cell replacement therapy. While NPIs offer advantages over other methods, optimizing their production for clinical use remains a challenge. The research compares NPI culturing in conventional static suspension methods (i.e., growing the stem cells in a suspension medium in a petri dish or beaker) with dynamic vertical wheel bioreactors (i.e., growing the same cells in a device that controls movement to mimic the body’s cell growth conditions). Early results suggest that dynamic culture systems may significantly enhance NPI production and quality, potentially improving islet morphology, viability, and functionality. This work could overcome critical hurdles in NPI production, bringing us closer to a more effective and accessible treatment for type 1 diabetes. The project aims to advance porcine islet differentiation strategies and transform diabetes care worldwide.

IMAGE: Suspension culture. Vertical wheel bioreactor.

Dr. Nayara Rampazzo Morelli

Postdoctoral Fellow

Supervisor: Dr. Peter Thompson, University of Manitoba

Investigating a potential drug target in human beta cells during type 1 diabetes

Type 1 diabetes (T1D) is well known for its autoimmune aspects which leads to loss of most of the beta cells in the body and insulin deficiency. How the process of beta cell loss occurs remains uncertain, but recent work indicates that the accumulation of stressed beta cells can accelerate T1D onset. Relieving the stressed beta cells slows the development of T1D in animal models but targets are lacking in humans, preventing us from determining whether this treatment approach could be moved to the clinic for T1D patients. The aim of this study is to evaluate a particular drug target in stressed human beta cells to determine whether this approach could be used to delay the progression of T1D or improve symptoms in people living with T1D.

(image from Dr. Thompson)

IMAGE: health beta cell. Senescent (dying) beta cell.


Dr. Shreyasi Sarkar

Postdoctoral Fellow,

Supervisor: Dr. Gareth Lim, Université de Montréal

Assessing the potential of targeting 14-3-3z to restore functional beta cell mass

Dr. Sarkar’s research focuses on identifying new ways to increase beta cell number (mass) to treat T1D. I study a protein called 14-3-3z, and earlier work from Dr. Lim showed that targeting this protein during early development in mice improved insulin secretion and beta cell mass, making this protein a promising target for diabetes treatment. Dr. Sarkar is now exploring a new approach using Antisense Oligonucleotides (a synthetic strand of nucleotide that can modulate protein expression) to target this protein after birth and explore whether similar improvements can be achieved. This may represent a new approach to treat diabetes.

(Image from https://www.ataxia.org/)

Sign up for our newsletter and stay connected